News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Pozen, Inc. Shares Up as FDA Decision Nears
August 1, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Shares of Chapel Hill drugmaker Pozen were up 6 percent in midday trading Wednesday ahead of a regulatory decision on the company's migraine drug.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Government
Cassidy Names Areas of Improvement for FDA’s Regulatory ‘Black Box’
February 19, 2026
·
3 min read
·
Tristan Manalac
Regulatory
It’s Official: FDA Will Now Default to One Clinical Trial for Drug Applications
February 19, 2026
·
3 min read
·
Tristan Manalac
CDC
NIH’s Jay Bhattacharya Steps In as Acting CDC Chief
February 18, 2026
·
1 min read
·
Annalee Armstrong
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
·
3 min read
·
Heather McKenzie